434 related articles for article (PubMed ID: 24158739)
41. [Efficacy and safety analysis of the combination of cladribine, cytarabine, granulocyte colonystimulating factor (CLAG) regime in patients with refractory or relapsed acute myeloid leukemia].
Duan MH; Zhang Y; Zhang M; Han X; Zhang Y; Yang C; Feng J; Zhang L; Zhang W; Li J; Tian LP; Zhang Y; Zhou DB
Zhonghua Xue Ye Xue Za Zhi; 2016 Jul; 37(7):571-5. PubMed ID: 27535856
[TBL] [Abstract][Full Text] [Related]
42. FLAMSA reduced-intensity conditioning is equally effective in AML patients with primary induction failure as well as in first or second complete remission.
Holtick U; Shimabukuro-Vornhagen A; Chakupurakal G; Theurich S; Leitzke S; Burst A; Hallek M; von Bergwelt-Baildon M; Scheid C; Chemnitz JM
Eur J Haematol; 2016 May; 96(5):475-82. PubMed ID: 26132980
[TBL] [Abstract][Full Text] [Related]
43. Successes and challenges in the treatment of pediatric acute myeloid leukemia: a retrospective analysis of the AML-BFM trials from 1987 to 2012.
Rasche M; Zimmermann M; Borschel L; Bourquin JP; Dworzak M; Klingebiel T; Lehrnbecher T; Creutzig U; Klusmann JH; Reinhardt D
Leukemia; 2018 Oct; 32(10):2167-2177. PubMed ID: 29550834
[TBL] [Abstract][Full Text] [Related]
44. Busulfan and fludarabine conditioning regimen given at hematological nadir of cytoreduction fludarabine, cytarabine, and idarubicin chemotherapy in patients with refractory acute myeloid leukemia undergoing allogeneic stem cell transplantation: a single arm pilot consort study.
Tang W; Fan X; Wang L; Hu J
Medicine (Baltimore); 2015 Apr; 94(15):e706. PubMed ID: 25881847
[TBL] [Abstract][Full Text] [Related]
45. Mito-FLAG with Ara-C as bolus versus continuous infusion in recurrent or refractory AML--long-term results of a prospective randomized intergroup study of the East German Study Group Hematology/Oncology (OSHO) and the Study Alliance Leukemia (SAL).
Thiel A; Schetelig J; Pönisch W; Schäfer-Eckart K; Aulitzky W; Peter N; Schulze A; Maschmeyer G; Neugebauer S; Herbst R; Hänel A; Morgner A; Kroschinsky F; Bornhäuser M; Lange T; Wilhelm M; Niederwieser D; Ehninger G; Fiedler F; Hänel M; ;
Ann Oncol; 2015 Jul; 26(7):1434-40. PubMed ID: 25922062
[TBL] [Abstract][Full Text] [Related]
46. Hematopoietic Stem Cell Transplantation From Haploidentical Donors in Aplasia After Cladribine/Cytarabine Chemotherapy for Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome.
Vydra J; Válková V; Čemusová B; Kolář M; Nováková L; Soukup P; Šálek C; Vraná M; Pytlík R; Lesný P; Vítek A; Cetkovský P; Marková M
Clin Lymphoma Myeloma Leuk; 2019 Jun; 19(6):365-371. PubMed ID: 30905537
[TBL] [Abstract][Full Text] [Related]
47. Impact on acute myeloid leukemia relapse in granulocyte colony-stimulating factor application: a meta-analysis.
Feng X; Lan H; Ruan Y; Li C
Hematology; 2018 Oct; 23(9):581-589. PubMed ID: 29516766
[TBL] [Abstract][Full Text] [Related]
48. Comparable survival for pediatric acute myeloid leukemia with poor-risk cytogenetics following chemotherapy, matched related donor, or unrelated donor transplantation.
Kelly MJ; Horan JT; Alonzo TA; Eapen M; Gerbing RB; He W; Lange BJ; Parsons SK; Woods WG
Pediatr Blood Cancer; 2014 Feb; 61(2):269-75. PubMed ID: 23955900
[TBL] [Abstract][Full Text] [Related]
49. Long-term disease-free survival after gemtuzumab, intermediate-dose cytarabine, and mitoxantrone in patients with CD33(+) primary resistant or relapsed acute myeloid leukemia.
Chevallier P; Delaunay J; Turlure P; Pigneux A; Hunault M; Garand R; Guillaume T; Avet-Loiseau H; Dmytruk N; Girault S; Milpied N; Ifrah N; Mohty M; Harousseau JL
J Clin Oncol; 2008 Nov; 26(32):5192-7. PubMed ID: 18854573
[TBL] [Abstract][Full Text] [Related]
50. Novel treatments for relapsed/refractory acute myeloid leukemia with
Tallis E; Borthakur G
Expert Rev Hematol; 2019 Aug; 12(8):621-640. PubMed ID: 31232619
[No Abstract] [Full Text] [Related]
51. FLAG-liposomal doxorubicin (Myocet) regimen for refractory or relapsed acute leukemia pediatric patients.
Quarello P; Berger M; Rivetti E; Galletto C; Masetti R; Manicone R; Barisone E; Pession A; Fagioli F
J Pediatr Hematol Oncol; 2012 Apr; 34(3):208-16. PubMed ID: 22395219
[TBL] [Abstract][Full Text] [Related]
52. Opportunities for immunotherapy in childhood acute myeloid leukemia.
Lamble AJ; Tasian SK
Hematology Am Soc Hematol Educ Program; 2019 Dec; 2019(1):218-225. PubMed ID: 31808843
[TBL] [Abstract][Full Text] [Related]
53. Outcome for children treated for relapsed or refractory acute myelogenous leukemia (rAML): a Therapeutic Advances in Childhood Leukemia (TACL) Consortium study.
Gorman MF; Ji L; Ko RH; Barnette P; Bostrom B; Hutchinson R; Raetz E; Seibel NL; Twist CJ; Eckroth E; Sposto R; Gaynon PS; Loh ML
Pediatr Blood Cancer; 2010 Sep; 55(3):421-9. PubMed ID: 20658611
[TBL] [Abstract][Full Text] [Related]
54. Long-Term Follow-Up and Impact of Comorbidity before Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Relapsed or Refractory Acute Myeloid Leukemia-Lessons Learned from the Prospective BRIDGE Trial.
Middeke JM; Herbst R; Parmentier S; Bug G; Hänel M; Stuhler G; Schäfer-Eckart K; Rösler W; Klein S; Bethge W; Bitz U; Büttner B; Knoth H; Alakel N; Schaich M; Morgner A; Kramer M; Sockel K; von Bonin M; Stölzel F; Platzbecker U; Röllig C; Thiede C; Ehninger G; Bornhäuser M; Schetelig J
Biol Blood Marrow Transplant; 2017 Sep; 23(9):1491-1497. PubMed ID: 28527985
[TBL] [Abstract][Full Text] [Related]
55. Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia.
Jabbour E; Garcia-Manero G; Cortes J; Ravandi F; Plunkett W; Gandhi V; Faderl S; O'Brien S; Borthakur G; Kadia T; Burger J; Konopleva M; Brandt M; Huang X; Kantarjian H
Clin Lymphoma Myeloma Leuk; 2012 Aug; 12(4):244-51. PubMed ID: 22534616
[TBL] [Abstract][Full Text] [Related]
56. Targeted Therapies in Pediatric Acute Myeloid Leukemia - Evolving Therapeutic Landscape.
Al-Antary ET; Gupte A; Ravindranath Y
Indian J Pediatr; 2024 Feb; 91(2):176-183. PubMed ID: 37450248
[TBL] [Abstract][Full Text] [Related]
57. Current and emerging therapies for acute myeloid leukemia.
Robak T; Wierzbowska A
Clin Ther; 2009; 31 Pt 2():2349-70. PubMed ID: 20110045
[TBL] [Abstract][Full Text] [Related]
58. Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial.
Cortes J; Perl AE; Döhner H; Kantarjian H; Martinelli G; Kovacsovics T; Rousselot P; Steffen B; Dombret H; Estey E; Strickland S; Altman JK; Baldus CD; Burnett A; Krämer A; Russell N; Shah NP; Smith CC; Wang ES; Ifrah N; Gammon G; Trone D; Lazzaretto D; Levis M
Lancet Oncol; 2018 Jul; 19(7):889-903. PubMed ID: 29859851
[TBL] [Abstract][Full Text] [Related]
59. Dose escalation of total marrow irradiation with concurrent chemotherapy in patients with advanced acute leukemia undergoing allogeneic hematopoietic cell transplantation.
Wong JY; Forman S; Somlo G; Rosenthal J; Liu A; Schultheiss T; Radany E; Palmer J; Stein A
Int J Radiat Oncol Biol Phys; 2013 Jan; 85(1):148-56. PubMed ID: 22592050
[TBL] [Abstract][Full Text] [Related]
60. Use of decitabine for patients with refractory or relapsed acute myeloid leukemia: a systematic review and meta-analysis.
Ma YY; Zhao M; Liu Y; Zhao DF; Wang LX; Chen XP; Li L
Hematology; 2019 Dec; 24(1):507-515. PubMed ID: 31242832
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
